Receptor alterations in Parkinson’s disease

  • N. Ogawa
  • M. Asanuma
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Not only dopamine but also enzymes involved in catecholamine synthesis and other biogenic amines have been found to decrease in the brain of PD patients; amino acid and neuropeptide levels also appear to be affected. Furthermore, changes in various neurotransmitter receptors have been detected by receptor studies. These studies are now effectively employed for the exploration of administration modalities with minimum side effects and for the development of new drugs as well as for the investigation of the action mechanisms of available agents.


Neurotensin Receptor Parkinsonian Brain Receptor Alteration Gaba Receptor Binding High Affinity Neurotensin Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bernheimer H, Birkmayer H, Hornykiewicz O (1961) Verteilung des 5-Hydroxy-tryptamins ( Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin Wochenschr 39: 1056–1059Google Scholar
  2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndrome of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 425–455Google Scholar
  3. Creeogse I, Lelf SE (1982) Dopamine receptors: a classification. J Clin Psychopharmacol 2: 329–335Google Scholar
  4. de Montis G, dBeaumont K, Jovoy-Agid F, Agid Y, Constandinidis J, Lowenthal A, Lloyd KG (1982) Glycine receptors in the human substantia nigra as defined by [3H]strychinine binding. J Neurochem 38: 718–724PubMedCrossRefGoogle Scholar
  5. Ehringer H, Hornykiewicz O (I960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytryramin) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239Google Scholar
  6. Guttman M, Seeman P (1987) Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-DOPA therapy. In: Yahr MD, Bergmann (eds) Advance in neurology, vol 45. Raven Press, New York, pp 51–57Google Scholar
  7. Klawans HL, Crosset P, Dana N (1975) Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-dopa-induced dyskinesia. In: Calne DB, Chase TN, Barbea A (eds) Advances in neurology, vol 9-Raven Press, New York, pp 105–112Google Scholar
  8. Klawans HL, Goetz C, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 2: 125–129CrossRefGoogle Scholar
  9. Langston, JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980PubMedCrossRefGoogle Scholar
  10. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61PubMedCrossRefGoogle Scholar
  11. Long A, Blair R (1984) Parkinson’s disease in 1984: an update. Can Med Assoc J 131: 1031–1037Google Scholar
  12. McGeer PL, McGeer EG (1976) Enzymes associated with the metabolism of catechol-amines, acetylcholine and GAB A in human controls and patients with Parkinson’s disease and Huntington’s chorea. J Neurochem 26: 65–76PubMedGoogle Scholar
  13. Mauborgne A, Javoy-Agid F, Legrand JC, Agid Y, Cesselin F (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brain. Brain Res 268: 167–170PubMedCrossRefGoogle Scholar
  14. Nagatsu T, Kanamori T, Kato T, Iizuka R, Narabayashi H (1978) Dopamine-stimulated adenylate cyclase activity in the human brain: changes in parkinsonism. Biochem Med 19: 360–365PubMedCrossRefGoogle Scholar
  15. Nagatsu T, Kato T, Nagatsu(sudo) Y, Ikuta K, Sano M, Nagatu I, Kondo Y, Inagaki S, Iizuka R, Hori A, Narabayashi H (1977) Phenylethanolamine N-methyltransferase and other ezymes of catecholamine metabolism in human brain. Clin Chim Acta 75: 221–232Google Scholar
  16. Nagatsu T, Yamaguchi T, Kato T, Sugimoto T, Matsuura S, Akino M, Nagatsu I, Iizuka R, Narabayashi H (1981) Biopterine in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta 109: 305–311PubMedCrossRefGoogle Scholar
  17. Ogawa N (1989) Parkinsonism induced by indeloxazine hydrochloride in the elderly. Clin Ther 11: 802–806PubMedGoogle Scholar
  18. Ogawa N, Mizuno S, Mori A, Kuroda H (1984) Chronic dihydroergotoxine administration sets on receptors for enkephalin and thyrotropin releasing hormone in the aged-rat brain. Peptides 5: 53–56PubMedCrossRefGoogle Scholar
  19. Ogawa N, Yamawaki Y, Kuroda H, Ofuji T (1981) Effects of bromocriptine on receptor binding of methionine-enkephalin. Neurosci Lett 23: 215–218PubMedCrossRefGoogle Scholar
  20. Ogawa N, Yamawaki Y, Kuroda H, Takayama H, Ota Z (1984) Differences in the effect of levodopa and bromocriptine on rat striatal dopamine receptors. Neurosciences (Kobe) 10: 259–266Google Scholar
  21. Perry TL, Javoy-Agid F, Agid Y, Fibiger HC (1983) Striatal GABAergic neuronal activity is not reduced in Parkinson’s disease. J Neurochem 40: 1120–1123PubMedCrossRefGoogle Scholar
  22. Quirion R, Larson TA, Calne D, Chase T, Rioux F, St-Pierre S, Evarist H, Pert A, Pert CB (1982) Analysis of [3H]neurotensin receptors by computed densitometry: visualization of control and peripheral neurotensin receptors. In: Nemeroff CB, Prange AJ (eds) Neurotensin: a brain and gastrointestinal peptide. Ann NY Acad Sci 400: 415–417Google Scholar
  23. Reisine TP, Fields JZ, Yamamura HI, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344PubMedCrossRefGoogle Scholar
  24. Reisine TD, Rosser M, Spokes E, Iversen L, Yamamura HI (1979) Alterations in brain opiate receptors in Parkinson’s disease. Brain Res 173: 378–392PubMedCrossRefGoogle Scholar
  25. Rinne UK (1982) Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Neurology 2: movement disorders. Butterworths, London, pp 59–74Google Scholar
  26. Rinne UK, Koskinen V, Laaksonen H, Löneberg P, Sonninen V (1978) GABA receptor binding in the parkinsonian brain. Life Sci 22: 2225–2228PubMedCrossRefGoogle Scholar
  27. Rinne UK, Koskinen V, Lönnberg P (1980) Neurotransmitter receptors in the parkinsonian brain. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease. Elsevier, Amsterdam, pp 93–107Google Scholar
  28. Rinne UK, Lönnberg P, Koskinen V (1981) Dopamine receptors in the parkinsonian brain. J Neural Transm 51: 97–106PubMedCrossRefGoogle Scholar
  29. Sadoul JL, Checler F, Kitabgi P, Rostene W, Javoy-Agid F, Vincent JP (1984) Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. Biochem Biophys Res Commun 125: 395–404PubMedCrossRefGoogle Scholar
  30. Shibuya M (1979) Dopamine-sensitive adenylate cylase activity in the striatum in Parkinson’s disease. J Neural Transm 44: 287–295PubMedCrossRefGoogle Scholar
  31. Studier JM, Javoy-Agid F, Cesselin F, Legrand JC, Agid Y (1982) CCK-8-Immurore-activity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. Brain Res 243: 176–179CrossRefGoogle Scholar
  32. Taquet H, Javoy-Agid F, Cesselin F, Hamon M, Legrand JC, Agid Y (1982) Microtopagraphy of methionine-enkephalin, dopamine and noradrenaline in the ventral messencephalon of human control and parkinsonian brains. Brain Res 235: 303–314PubMedCrossRefGoogle Scholar
  33. Taquet H, Javoy-Agid F, Hanon M, Legrand JC, Agid Y, Cesselin F (1983) Parkinson’s disease affects differently Met- and Leu-enkephaline in the human brain. Brain Res 280: 379–382PubMedCrossRefGoogle Scholar
  34. Teychenne PF, Bergsrud D, Racy A, Vern B (1981) Low dose bromocriptine therapy in Parkinson’s disease. Res Clin Forums 3: 37–47Google Scholar
  35. Uhl GR, Whitehouse PJ, Poice DL, Tourtelotte WW, Kuhar MJ (1984) Parkinson’s disease: depletion of substantia nigra neurotensin receptors. Brain Res 308: 186–190PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • N. Ogawa
    • 1
  • M. Asanuma
    • 1
  1. 1.Department of Neurochemistry, Institute for NeurobiologyOkayama University Medical SchoolOkayama 700Japan

Personalised recommendations